Alkermes said its orexin agonist ALKS 7290 showed a signal of efficacy in a randomized Phase 1 study for ADHD, while reporting the therapy was well tolerated. The company presented early data in participants starting with moderate-to-severe symptom scores. After two weeks, Alkermes reported symptom improvements at the higher 50 mg dose, with the scale moving from moderate-to-severe toward mild. The early-stage dataset may influence how the company positions orexin agonism beyond sleep disorders.